Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue sup1: Insulin glargine for the treatment of T1 and T2 diabetes / Guest Editors: S Dixon and J R Peters
Submit an article Journal homepage
162
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

Phil McEwan School of Mathematics, Cardiff University, Cardiff, UKCorrespondence[email protected]
,
Chris D. Poole Cardiff Research Consortium, Heath Park, Cardiff, UK
,
Tony Tetlow Cardiff Research Consortium, Heath Park, Cardiff, UK
,
Paul Holmes sanofi-aventis UK, Guildford, Surrey, UK
&
Craig J. Currie Department of Medicine, School of Medicine, Cardiff University, Cardiff, UK
Pages S21-S31 | Accepted 11 Jan 2007, Published online: 07 Feb 2007

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Asrul Akmal Shafie & Chin Hui Ng. (2020) Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia. ClinicoEconomics and Outcomes Research 12, pages 333-343.
Read now
Martin Ridderstråle, Marie Markert Jensen, Rasmus Prior Gjesing & Leo Niskanen. (2013) Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden. Journal of Medical Economics 16:4, pages 468-478.
Read now
Craig J. Currie, Chris D. Poole & Natalie L. Papo. (2009) An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. Current Medical Research and Opinion 25:10, pages 2389-2400.
Read now
MA Elrishi, J Jarvis, K Khunti & MJ Davies. (2008) Insulin glargine and its role in glycaemic management of Type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 4:8, pages 1099-1110.
Read now
Cecilia M Lansang & Laurence Kennedy. (2007) Insulin glargine: a basal insulin for the management of diabetes. Expert Review of Endocrinology & Metabolism 2:5, pages 573-585.
Read now
Simon Dixon & John R. Peters. (2007) Evaluating the ‘real’ cost-effectiveness of health technology: reconciling the public interest with patients’ interests. Current Medical Research and Opinion 23:sup1, pages S1-S6.
Read now

Articles from other publishers (11)

Marzieh Nosrati, Soroush Ahmadi Fariman, Parisa Saiyarsarai & Shekoufeh Nikfar. (2023) Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran. Journal of Diabetes & Metabolic Disorders 22:1, pages 817-825.
Crossref
Mohsen Pakdaman, Rahele Akbari, Hamid Reza Dehghan, Reza Valagohar, Parastoo Rostami & Mahdieh Namayandeh. (2019) The Cost-effectiveness of Analogue Insulin Pens in Comparison with Human Insulin Pens for Controlling Type 1, Type 2, and Gestational Diabetes: A Systematic Review Article. Health Technology Assessment in Action In Press:In Press.
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Phil McEwan, Hayley Bennett, Jonathan Fellows, Jennifer Priaulx & Klas Bergenheim. (2016) The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. PLOS ONE 11:9, pages e0162441.
Crossref
Unchalee Permsuwan, Nathorn Chaiyakunapruk, Piyameth Dilokthornsakul, Kednapa Thavorn & Surasak Saokaew. (2016) Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. Applied Health Economics and Health Policy 14:3, pages 281-292.
Crossref
Julio Rosenstock, Vivian Fonseca, Stefan Schinzel, Marie-Paule Dain, Peter Mullins & Matthew Riddle. (2014) Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. Journal of Diabetes and its Complications 28:5, pages 742-749.
Crossref
Cosimo Giannini, Angelika Mohn & Francesco Chiarelli. (2009) Technology and the issue of cost/benefit in diabetes. Diabetes/Metabolism Research and Reviews 25:S1, pages S34-S44.
Crossref
Bernhard Ludvik, Helmut Brath, Thomas Wascher & Hermann Toplak. (2009) Stellenwert von Langzeit-Insulin-Analoga in der Therapie des Diabetes mellitus Typ 2The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus. Wiener klinische Wochenschrift 121:13-14, pages 473-482.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
. (2013) Insulin glargine adds up to value for diabetes in the UK. PharmacoEconomics & Outcomes News 528:1, pages 3-4.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.